Unknown

Dataset Information

0

Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies.


ABSTRACT: Neuroendocrine neoplasms (NENs) encompass a heterogeneous group of tumors. Whereas low-grade neuroendocrine tumors (NETs) are histologically well-differentiated, highly aggressive neuroendocrine carcinomas (NECs) are characterized by a high proliferation rate and a worse clinical outcome. Since most NEN patients need monitoring of tumor progress and response to treatment for a long period of time, especially in metastatic disease, reliable, dynamic, and easy-to-assess biomarkers are needed. In this prospective study, we identified platelet-expressed synaptophysin (pSyn) as a novel biomarker in NENs. The level of pSyn in NENs was significantly upregulated compared to healthy donors. pSyn was positively correlated with higher tumor stages, the occurrence of metastasis, histological grading, and higher tumor proliferation (Ki67). Most importantly, high pSyn expression in our NEN cohort was shown to predict shorter progression-free survival (PFS). In conclusion, our data highlight the potential of pSyn as a novel biomarker in NENs reflecting tumor stages, grading, and prognosis.

SUBMITTER: Hinterleitner M 

PROVIDER: S-EPMC8150833 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Platelet-Expressed Synaptophysin (pSyn) as Novel Biomarker in Neuroendocrine Malignancies.

Hinterleitner Martina M   Sipos Bence B   Wagner Verena V   Grottenthaler Julia M JM   Lauer Ulrich M UM   Zender Lars L   Hinterleitner Clemens C  

Cancers 20210511 10


Neuroendocrine neoplasms (NENs) encompass a heterogeneous group of tumors. Whereas low-grade neuroendocrine tumors (NETs) are histologically well-differentiated, highly aggressive neuroendocrine carcinomas (NECs) are characterized by a high proliferation rate and a worse clinical outcome. Since most NEN patients need monitoring of tumor progress and response to treatment for a long period of time, especially in metastatic disease, reliable, dynamic, and easy-to-assess biomarkers are needed. In t  ...[more]

Similar Datasets

| S-EPMC5380546 | biostudies-literature
| S-EPMC554981 | biostudies-literature
| S-EPMC8789097 | biostudies-literature
| S-EPMC5933774 | biostudies-literature
| S-EPMC3632533 | biostudies-literature
| S-EPMC9101303 | biostudies-literature
| S-EPMC9599522 | biostudies-literature
| S-EPMC9139575 | biostudies-literature
| S-EPMC9937688 | biostudies-literature
| S-EPMC8870162 | biostudies-literature